Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...
The top three pharmacy benefit managers hiked the prices of dozens of 'specialty' generic drugs, some by more than 1000% of ...
Private investment firm Bridgewest is combing its Australia-based biologics CDMO BioCina and its sterile injectable ...
Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...
For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way … Get ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...
Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle ...
The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower ...
In the 10th megaround of 2025, Umoja Biopharma has banked $100 million in a Series C fundraise with an eye to advancing its pipeline of in vivo CAR-T cell therapies for cancer and autoimmune diseases.
Health tech sees strong start to 2025 with five $100M+ funding rounds, including Evergreen Nephrology, Qventus, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback